Drug Response Dx GmbH announced that it has received funding from High-Tech Gründerfonds Management GmbH and Qiagen NV.
January 06, 2013 at 11:00 pm
Drug Response Dx GmbH announced that it has received its seed round of funding from new investors Qiagen NV and High-Tech Gründerfonds Management GmbH on January 7, 2013. Qiagen NV has made a strategic equity investment in the company. The terms of the transaction were not disclosed. High-Tech Gründerfonds Management GmbH invested through its fund High-Tech Gründerfonds II GmbH und Co. KG.
On January 7, 2013, Drug Response Dx GmbH closed the transaction.